Login to Your Account



Maxim's Ceplene Hits Primary Endpoint In AML Phase III Trial

By Karen Pihl-Carey


Thursday, May 13, 2004
Meeting its primary endpoint in a Phase III trial, Ceplene proved itself not only as a potential lifesaver for acute myeloid leukemia patients, but also as an immune modulator that can show benefit in different classes of cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription